CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30

CITIUS ONCOLOGY, INC.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.71−0.06 (-7.49%)

Close on Oct 19, 2026

Market cap: $76.65M
P/E (TTM): –
Dividend yield: –

CITIUS ONCOLOGY, INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-09-30	FY 2022 2022-12-31
Stock-Based Compensation	8.32	–
Deferred Income Taxes	1.06	–
Change in Inventory	-13	–
Change in Accounts Payable	9.52	–
Change in Unearned Revenue	–	0.13
Operating Cash Flow	-5.49	-0.05
Purchase of Investments	–	-67
Investing Cash Flow	-5.75	-67
Stock Issued	15	66
Financing Cash Flow	15	68
Net Change in Cash	–	0.29
Interest Paid	0.19	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -109.5%

Financial strength

Current ratio: 0.73
Debt to equity: 0.16
Debt to assets: 5.7%
Cash to current liabilities: 28.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.90
Dividend yield: –